Can a triple-drug combination tame AML without intensive chemo?
NCT ID NCT07722767
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This trial tests whether adding an experimental drug called CLN 049 to two standard AML drugs (azacitidine and venetoclax) is safe and tolerable for adults newly diagnosed with acute myeloid leukemia who are not candidates for intensive chemotherapy. The study will first find the best dose of CLN 049 and then expand to see how well the combination works. About 90 participants will take part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called CLN 049 combined with azacitidine and venetoclax
- What this could lead to
- If it works, this combination could offer a new, less intensive treatment option for people with AML who cannot tolerate standard chemotherapy.
- What could go wrong
- This is an early phase 1b trial, so the main goals are safety and finding the right dose. It is too soon to know if the combination will be effective, and there may be unknown side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope
Duarte, California, 91010, United States
Contact
-
MD Anderson
Houston, Texas, 77030, United States
Contact
-
New York University Langone Health
New York, New York, 10016, United States
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized dosing may improve stem cell transplant survival in blood cancer patients
- New Triple-Drug strategy aims to boost remission in Hard-to-Treat leukemia
- New drug cocktail aims to boost remission in tough AML cases
- New hope for blood cancer patients: daily pill aims to prevent relapse without transplant
- New stem cell combo could boost survival in blood cancer patients
- New cell therapy aims to stop blood cancer relapse in tough-to-treat patients